Delving into the Latest Updates on TLL Pharmaceutical, LLC with Synapse

A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of TLL018 for Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis

A study to investigate the safety and efficacy of TLL018 compared with placebo in subjects with moderate to severe ulcerative colitis.

开始日期2022-12-30

申办/合作机构

TLL Pharmaceutical, LLC

NCT04243083 / Completed临床1期

A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single and Multiple Ascending Dose (SAD/MAD) Study in Healthy Subjects To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Of TLL018 Following Oral Administration And With An Open Label Food Effect Panel

TLL018 is developed for treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. The purposes of this study are (1) determining if and at what doses TLL018 is safe and can be tolerated when administered to humans, (2) assessing what TLL018 does to the body and how the body responds to TLL018 when given as single and multiple doses, and (3) assessing potential food effect on TLL018.

开始日期2020-01-26

申办/合作机构

TLL Pharmaceutical, LLC

100 项与 TLL Pharmaceutical, LLC 相关的临床结果

登录后查看更多信息

0 项与 TLL Pharmaceutical, LLC 相关的专利（医药）

登录后查看更多信息

100 项与 TLL Pharmaceutical, LLC 相关的药物交易

登录后查看更多信息

100 项与 TLL Pharmaceutical, LLC 相关的转化医学

登录后查看更多信息